AB Science announces that the European Academy of Allergy & Clinical Immunology (EAACI) 2020 Annual Congress has accepted its phase 3 study results with masitinib in severe asthma to be delivered as a late breaking oral presentation

Paris, 7 May 2020, 6.45pm

The European Academy of Allergy & Clinical Immunology (EAACI) 2020 Annual Congress has accepted AB Science phase 3 study AB07015 results with masitinib in severe asthma to be delivered as a late breaking oral presentation

AB Science SA (Euronext - FR0010557264 - AB) today announced that an abstract reporting findings from its Phase 3 AB07015 study on severe asthma uncontrolled by oral corticosteroids, has been selected for an oral platform presentation at the upcoming European Academy of Allergy & Clinical Immunology (EAACI) 2020 Congress, which this year will be held digitally June 6-8, 2020.

Lavinia Davidescu (MD, PhD), Professor of Pulmonology at the University of Oradea, Romania, and coordinating investigator of study AB07015, will present key data from this positive Phase 3 trial as part of a Late Breaking Oral Abstract Session entitled ‘Allergy Diagnosis and Asthma’.

EAACI is one of the most prestigious academic meetings for pulmonary medicine and the world’s largest congress specializing in the field of allergy and clinical immunology. The Annual Congress regularly attracts 7,000-8,000 participants and experts from across the globe. Due to the current COVID-19 pandemic, EAACI will deliver the Annual Congress 2020 as a digital event consisting of pre-recorded content available beginning June 6, 2020 on the EAACI website.

Presented abstract texts will also be published on the EAACI Media Library and in the official EAACI journal ‘Allergy’ after the congress.

Professor Lavinia Davidescu said: “Unlike other drugs for severe asthma, masitinib targets the dual mechanisms of mast cell-related asthma pathophysiology and PDGFR-related airway remodeling. Selection of this abstract for a late breaking oral presentation at the upcoming Digital 2020 EAACI Congress is an indication of the interest being generated by this innovative approach and masitinib’s potential impact on the treatment paradigm for severe asthma.”

Olivier Hermine (President of the Scientific Committee of AB Science and member of the Académie des Sciences in France) said: “Biologics for severe asthma are typically only effective in patients with a high eosinophil count of greater than 300 cells/µL. In contrast, masitinib is effective across a broad population, regardless of the eosinophil level, and may therefore provide a new treatment option for biologic-ineligible patients or patients in failure to biologics”.